UBS lowered the firm’s price target on Genmab to DKK 2,750 from DKK 2,800 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- M&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8B
- Genmab Expands Oncology Reach with ProfoundBio Buyout
- Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
- Genmab A/S Advances Its Share Buy-back Program
- Transactions in Connection with Share Buy-back Program
